Pediatric cancers are considered rare diseases, which makes them more challenging to study and treat. However, efforts like the Childhood Cancer Data Initiative are helping to further disease biology understanding and open pathways for community collaboration. In light of Childhood Cancer Awareness Month, NCI experts discuss the future of advancements such as precision medicine and immunotherapy.
(this only appears for logged-in users)
NCI is pushing the "bench to bedside" paradigm to bring medical advances into the clinic.
Dr. Nirali Shah, Hematologic Malignancies Section Head, Pediatric Oncology, NCI
Dr. Christine Heske, Translational Sarcoma Biology Group Head, Pediatric Oncology, NCI